Novo Nordisk A/S $NVO Holdings Decreased by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 47.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 14,930 shares of the company’s stock after selling 13,660 shares during the period. Union Bancaire Privee UBP SA’s holdings in Novo Nordisk A/S were worth $549,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NVO. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC grew its position in Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. grew its position in Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $314,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $48.01 on Monday. The firm has a market cap of $214.36 billion, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 4.33 and a beta of 0.78. The company’s fifty day moving average is $43.79 and its 200-day moving average is $45.82. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NVO shares. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. The Goldman Sachs Group reissued a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.